Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 11/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TOP2A | P11388 | 3/20 | 0.49 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312097 | 0.82 | TAAR1 (0.46) | ALDH1A1HPGDCASP1CASP7HSD17B10 | |
| SCHEMBL7724245 | 0.82 | NQO2 (0.50) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL7858304 | 0.81 | MAPK8 (0.32) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL7732998 | 0.79 | HTT (0.41) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL7724232 | 0.77 | PRMT1 (0.45) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL7735075 | 0.77 | NQO2 (0.47) | NQO2PRMT1ALDH1A1TOP1HPGD | |
| SCHEMBL15149748 | 0.77 | L3MBTL1 (0.42) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL17826868 | 0.77 | PRSS1 (0.37) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6447487 | 0.73 | PRSS1 (0.34) | HSD17B10F2F10PRSS1PRSS2 | |
| SCHEMBL21168095 | 0.73 | NPC1 (0.51) | ALDH1A1HPGDHSD17B10F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| EP-0792271-B1 | FURAN DERIVATIVES FOR INHIBITING PNEUMOCYSTIS CARINII PNEUMONIA, GIARDIA LAMBLIA AND CRYPTOSPORIDIUM PARVUM | UNIV GEORGIA STATE RES FOUND (US) | 2002-02-27 | — | — | EP | claimed |
| US-5602172-A | USING A 2,5-DIPHENYLFURAN COMPOUND | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-02-11 | — | — | US | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2121700-B1 | SUBSTITUTED TETRAHYDROQUINOLINES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | FINSINGER DIRK (DE) | 2012-05-24 | — | — | US | disclosed |
| US-8110583-B2 | treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle | MERCK PATENT GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| EP-2033959-B1 | Tetrahydropyranoquinoline derivatives | MERCK PATENT GMBH (DE) | 2011-04-27 | — | — | EP | disclosed |
| US-7915416-B2 | Tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| WO-2005108355-A2 | DIHYDROBENZOTHIOPHENES | MERCK PATENT GMBH (DE) | 2005-11-17 | — | — | WO | disclosed |
| CN-1681511-A | Combinations of drugs for the treatment of neoplasms | COMBINATORX INC (US) | 2005-10-12 | — | — | CN | disclosed |
| WO-2005063735-A1 | 2-(HETERO)-ARYL-SUBSTITUTED TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137185-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INCORPORATED | 2005-06-23 | — | — | US | disclosed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | disclosed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-0792271-B1 | FURAN DERIVATIVES FOR INHIBITING PNEUMOCYSTIS CARINII PNEUMONIA, GIARDIA LAMBLIA AND CRYPTOSPORIDIUM PARVUM | UNIV GEORGIA STATE RES FOUND (US) | 2002-02-27 | — | — | EP | disclosed |
| US-5602172-A | USING A 2,5-DIPHENYLFURAN COMPOUND | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | TP53, IDH3A, IDH2 | NQO2 20/4885PRMT1 26/4885ALDH1A1 347/4885 |
| US-20050137185-A1 | Combinations of drugs for the treatment of neoplasms | MKI67, DHFR, IL5 | NQO2 338/4885PRMT1 2226/4885ALDH1A1 412/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | NQO2 132/4885PRMT1 2584/4885ALDH1A1 662/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | NQO2 129/4885PRMT1 1095/4885ALDH1A1 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.